{"product_id":"cigna-swot-analysis","title":"Cigna SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCigna’s robust integrated care platform and global scale drive competitive strength, but regulatory headwinds and margin pressure from rising medical costs present clear challenges; emerging opportunities in digital health and value-based care could accelerate growth if execution remains disciplined. Purchase the full SWOT analysis to access a professionally formatted, editable report with detailed insights, financial context, and strategic recommendations to guide investments or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Evernorth Health Services Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEvernorth Health Services is Cigna’s primary growth engine, supplying PBM (pharmacy benefit management) and specialty pharmacy services that accounted for roughly 58% of Cigna’s $225 billion revenue run-rate through 2025 and drove a majority of 2025 adjusted EPS growth.\u003c\/p\u003e\n\u003cp\u003eThe segment’s integrated pharmacy, behavioral health, and clinical care programs reduced total cost of care for select large-employer clients by ~7–12% in 2024 pilots, creating a measurable ROI for buyers.\u003c\/p\u003e\n\u003cp\u003eEvernorth’s scale—managing over 80 million pharmacy claims annually and specialty pipelines exceeding $18 billion in spend—gives Cigna negotiating leverage and cross-sell opportunities with health plans and large employers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership in Specialty Pharmacy Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough Accredo, Cigna holds a top specialty pharmacy position, serving over 1.1 million specialty patients in 2024 and capturing higher-margin biologic fills as specialty drugs drove 55% of pharmacy spend growth that year.\u003c\/p\u003e\n\u003cp\u003eAccredo’s scale—$10.2 billion specialty pharmacy revenue in 2024—creates a moat: integrated distribution, clinical programs, and payer ties that smaller entrants struggle to match.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Free Cash Flow and Capital Allocation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCigna (CI) generated $7.8 billion in operating cash flow and $5.2 billion in free cash flow through FY 2024, enabling a disciplined capital plan of rising dividends and $10+ billion in share repurchases authorized through 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Global Health Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpcigna operates across north america europe asia and the middle east offering medical dental supplemental plans to over million customers globally as of reducing dependence on any single market regulatory regime.\u003e\n\u003cpthis geographic spread grants access to emerging markets where middle-class healthcare spending grew cagr while diversified product lines helped cigna report revenue of billion smoothing regional downturns.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e180 million customers (2025)\u003c\/li\u003e\n\u003cli\u003e$174.2B revenue (2024)\u003c\/li\u003e\n\u003cli\u003eEmerging-market healthcare spend ~6% CAGR (2020–2024)\u003c\/li\u003e\n\u003cli\u003eMultiple product lines: medical, dental, supplemental\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pcigna\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Data Analytics and Health Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCigna has invested over $1.2 billion in proprietary data analytics and value-based care programs through 2024, using predictive models to lower total cost of care and improve clinical outcomes for members.\u003c\/p\u003e\n\u003cp\u003eIts analytics identify high-risk patients early—Cigna reported a 7–12% reduction in avoidable ER visits and a 4% drop in inpatient admissions in pilot populations in 2023—enabling targeted preventative interventions.\u003c\/p\u003e\n\u003cp\u003eThese capabilities support personalized care management as payers shift to data-driven, value-based contracts; Cigna’s analytics underpin care pathways across its 20+ million medical customers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInvestment: $1.2B+ through 2024\u003c\/li\u003e\n\u003cli\u003eER visits down: 7–12% (2023 pilots)\u003c\/li\u003e\n\u003cli\u003eInpatient admissions down: 4% (2023 pilots)\u003c\/li\u003e\n\u003cli\u003eCovered lives: 20+ million medical customers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCigna: PBM \u0026amp; Specialty Powerhouse—$174B Revenue, 180M Customers, $10B+ Accredo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEvernorth (PBM + specialty) drove most 2025 adjusted EPS growth, handling 80M pharmacy claims and $18B+ specialty pipeline; Accredo served 1.1M specialty patients and generated $10.2B in specialty revenue (2024). Cigna reported $174.2B revenue (2024), 180M customers (2025), $7.8B operating cash flow and $5.2B free cash flow (FY2024), plus $1.2B+ analytics spend to cut costs and admissions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$174.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomers (2025)\u003c\/td\u003e\n\u003ctd\u003e180M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccredo specialty rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$10.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy claims\/year\u003c\/td\u003e\n\u003ctd\u003e80M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp CF \/ Free CF (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$7.8B \/ $5.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalytics spend (through 2024)\u003c\/td\u003e\n\u003ctd\u003e$1.2B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework for analyzing Cigna’s business strategy by highlighting internal capabilities, operational weaknesses, market opportunities, and external threats shaping its competitive position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Cigna SWOT snapshot for rapid strategic alignment and clear executive briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Reliance on PBM Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA substantial share of Cigna’s 2024 adjusted operating income—about 20–25% based on Express Scripts PBM contribution reported in L3Harris filings and Cigna’s 2024 10-K—comes from pharmacy benefit management (PBM), a unit facing intense regulatory scrutiny in the US in 2024–25.\u003c\/p\u003e\n\u003cp\u003eThis concentration leaves Cigna’s margins exposed if Congress or states force rebate restructuring or mandated price transparency; analysts model a 5–12% EPS downside in stressed PBM reform scenarios.\u003c\/p\u003e\n\u003cp\u003eInvestors flag this reliance as a comparative risk versus insurers with larger fee-for-service or diversified product mixes, lowering relative valuation multiples by ~0.5–1.0x P\/E in 2025 consensus adjustments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLagging Presence in Medicare Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCigna lags peers in Medicare Advantage (MA): as of 2024 UnitedHealth (Optum) held ~6.1 million MA members and Humana ~5.5 million, while Cigna's MA enrollment remained under 1.0 million, limiting its exposure to the fast-growing senior market. This smaller footprint curbs Cigna's ability to capture MA's higher margins and predictable government revenue—MA premiums accounted for ~40% of Humana's 2024 revenue. Cigna is expanding but still behind.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Debt Levels from Historical Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWhile Cigna manages leverage, debt from the 2018 Express Scripts acquisition still shapes its credit profile; net debt was about $43.5 billion at year-end 2024, per company filings. Sustained higher U.S. interest rates in 2024–2025 pushed annual interest expense up roughly 20% year-over-year, tightening free cash flow and limiting capital for new large deals. The executive team must balance servicing this debt with funding growth initiatives to avoid credit-rating pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity of the Integrated Business Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe sheer scale and integration of Cigna's insurance, Express Scripts pharmacy, and Evernorth clinical services creates major operational complexity, contributing to $204.6B consolidated revenue in 2024 but slowing internal coordination and decision speed.\u003c\/p\u003e\n\u003cp\u003eThat complexity can lengthen response times to market shifts versus nimble specialists and raises compliance costs across distinct regulatory regimes (state insurance, federal pharma, and healthcare delivery).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $204.6B; integration heightens coordination risk\u003c\/li\u003e\n\u003cli\u003eMultiple regulatory regimes increase admin and compliance costs\u003c\/li\u003e\n\u003cli\u003eSlower market response vs specialized competitors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Exposure to the Commercial Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCigna’s revenue mix is concentrated in employer-sponsored commercial plans—about 65% of 2024 revenue came from commercial customers, making it sensitive to GDP and payroll trends.\u003c\/p\u003e\n\u003cp\u003eDuring economic slowdowns or rising unemployment, membership and premium growth can weaken; for example, a 1% rise in U.S. unemployment historically cuts employer coverage enrollment by ~0.8%. \u003c\/p\u003e\n\u003cp\u003eThis bias increases exposure to corporate benefit cuts versus peers with larger government (Medicare\/Medicaid) mixes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~65% 2024 revenue from commercial\u003c\/li\u003e\n\u003cli\u003e~0.8% enrollment drop per 1% unemployment rise\u003c\/li\u003e\n\u003cli\u003eHigher sensitivity to corporate benefit spending\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCigna faces PBM reform risk, high leverage, and commercial exposure capping EPS upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy PBM reliance (20–25% of 2024 adjusted operating income) exposes Cigna to 5–12% EPS downside under PBM reform; net debt ~$43.5B (YE2024) raises interest burden; Medicare Advantage enrollment \u0026lt;1.0M limits access to higher-margin seniors; 65% of 2024 revenue from commercial plans increases sensitivity to GDP\/unemployment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM share of operating income\u003c\/td\u003e\n\u003ctd\u003e20–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$43.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMA enrollment\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.0M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial revenue share\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eCigna SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get, and it reflects the same structure, depth, and editable content available after checkout. Purchase unlocks the complete, detailed version ready for immediate download and use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752650387833,"sku":"cigna-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/cigna-swot-analysis.png?v=1772243513","url":"https:\/\/growthsharematrix.com\/products\/cigna-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}